|
Gene: KCTD15 |
Gene summary for KCTD15 |
Gene summary. |
Gene information | Species | Human | Gene symbol | KCTD15 | Gene ID | 79047 |
Gene name | potassium channel tetramerization domain containing 15 | |
Gene Alias | KCTD15 | |
Cytomap | 19q13.11 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q96SI1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79047 | KCTD15 | C04 | Human | Oral cavity | OSCC | 4.45e-10 | 5.04e-01 | 0.2633 |
79047 | KCTD15 | C30 | Human | Oral cavity | OSCC | 6.06e-21 | 6.87e-01 | 0.3055 |
79047 | KCTD15 | C46 | Human | Oral cavity | OSCC | 9.88e-11 | 2.31e-01 | 0.1673 |
79047 | KCTD15 | C51 | Human | Oral cavity | OSCC | 1.83e-02 | 2.40e-01 | 0.2674 |
79047 | KCTD15 | C08 | Human | Oral cavity | OSCC | 4.96e-05 | 2.09e-01 | 0.1919 |
79047 | KCTD15 | LP17 | Human | Oral cavity | LP | 1.19e-02 | 3.29e-01 | 0.2349 |
79047 | KCTD15 | SYSMH1 | Human | Oral cavity | OSCC | 7.06e-03 | 1.05e-01 | 0.1127 |
79047 | KCTD15 | SYSMH2 | Human | Oral cavity | OSCC | 7.05e-09 | 2.66e-01 | 0.2326 |
79047 | KCTD15 | SYSMH3 | Human | Oral cavity | OSCC | 4.38e-12 | 3.52e-01 | 0.2442 |
79047 | KCTD15 | male-WTA | Human | Thyroid | PTC | 6.75e-05 | 5.88e-02 | 0.1037 |
79047 | KCTD15 | PTC07 | Human | Thyroid | PTC | 4.81e-03 | 2.65e-02 | 0.2044 |
79047 | KCTD15 | ATC13 | Human | Thyroid | ATC | 2.37e-37 | 7.40e-01 | 0.34 |
79047 | KCTD15 | ATC2 | Human | Thyroid | ATC | 5.12e-06 | 5.84e-01 | 0.34 |
79047 | KCTD15 | ATC3 | Human | Thyroid | ATC | 2.82e-03 | 3.02e-01 | 0.338 |
79047 | KCTD15 | ATC5 | Human | Thyroid | ATC | 1.72e-39 | 8.16e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051259 | Oral cavity | OSCC | protein complex oligomerization | 121/7305 | 238/18723 | 1.29e-04 | 9.21e-04 | 121 |
GO:00512591 | Oral cavity | LP | protein complex oligomerization | 85/4623 | 238/18723 | 8.81e-05 | 1.11e-03 | 85 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KCTD15 | SNV | Missense_Mutation | c.214N>A | p.Ala72Thr | p.A72T | Q96SI1 | protein_coding | tolerated(0.17) | benign(0.438) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
KCTD15 | SNV | Missense_Mutation | rs776384769 | c.485N>A | p.Arg162His | p.R162H | Q96SI1 | protein_coding | tolerated(0.57) | benign(0.001) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCTD15 | SNV | Missense_Mutation | novel | c.134T>C | p.Ile45Thr | p.I45T | Q96SI1 | protein_coding | deleterious(0.04) | benign(0.177) | TCGA-A5-A7WJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCTD15 | SNV | Missense_Mutation | c.455G>A | p.Arg152His | p.R152H | Q96SI1 | protein_coding | tolerated(0.07) | benign(0.026) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
KCTD15 | SNV | Missense_Mutation | novel | c.412G>A | p.Ala138Thr | p.A138T | Q96SI1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCTD15 | SNV | Missense_Mutation | novel | c.374N>T | p.Pro125Leu | p.P125L | Q96SI1 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCTD15 | SNV | Missense_Mutation | rs752211601 | c.101N>A | p.Arg34Gln | p.R34Q | Q96SI1 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.544) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCTD15 | SNV | Missense_Mutation | rs574787608 | c.734N>T | p.Ala245Val | p.A245V | Q96SI1 | protein_coding | deleterious(0.04) | possibly_damaging(0.691) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
KCTD15 | SNV | Missense_Mutation | rs748743699 | c.251G>A | p.Arg84His | p.R84H | Q96SI1 | protein_coding | deleterious(0.04) | probably_damaging(0.937) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCTD15 | SNV | Missense_Mutation | c.313N>T | p.Arg105Trp | p.R105W | Q96SI1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |